ArticleIJID regions2026
Home care for patients with COVID-19: Niger's experience; about 2037 cases in the city of Niamey.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to describe the epidemiologic, clinical, therapeutic, and clinical course profiles of patients receiving home care for COVID-19 in the city of Niamey. Methods: This was a descriptive, retrospective, cross-sectional study conducted over a 1-year period, from April 2020 to March 2021, focusing on the management of patients with COVID-19 in Niamey. All patients presenting with a mild form of the disease, identified and monitored by mobile teams, were included in this study. Results: A total of 2037 patients were included. Men accounted for 69.1% (n = 1407). The mean age was 39 ± 15.1 years, ranging from 1 to 86 years. Screening of index cases accounted for 69.3% of diagnostic circumstances. Comorbidities were present in 24.4% of patients (n = 497), and 63.6% (n = 1295) were asymptomatic. Hydroxychloroquine and/or azithromycin were used in 98.7% of cases (n = 2010), and adverse effects related to hydroxychloroquine were observed in 1.0% (n = 19) of patients. During follow-up, 3.9% (n = 79) of patients were subsequently hospitalized. In total, 94.9% (n = 1932) were declared recovered, of whom 74.3% (n = 1432) between the 10th and 15th day of treatment. Finally, 0.7% (n = 15) of patients died, representing 19.0% of those who were subsequently hospitalized. Conclusion: The favorable outcome observed in the majority of patients demonstrates the effectiveness of home care for mild forms of COVID-19, enabling early detection of severe cases and rapid intervention. However, prevention remains the best way to combat this pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.